Summary
Breast cancer is the most common cancer in women worldwide. Familial breast cancer (FBC) is expected to account for up to 15% of breast cancers. Although recent breakthroughs have resulted in the identification of distinct new groups of genetically inherent breast cancer genes, about 64% of the genetic predisposition to FBC remains unexplained. Therefore, new approaches are required to identify remaining genetic factors underlying FBC susceptibility. This is crucial because the elucidation of inherent cancer defects offers the ability to counsel and monitor patients. Importantly, it also provides firm ground for therapeutically targeting particular cancer pathways for example through Poly ADP-ribose polymerase inhibitors (PARPi) that exploit synthetic lethality with particular DNA repair deficiencies.
To advance the field, my host lab has performed High-Throughput phenotypic screen, based on gene variants recognized in a FBC cohort of 135 early-onset (age
To advance the field, my host lab has performed High-Throughput phenotypic screen, based on gene variants recognized in a FBC cohort of 135 early-onset (age
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/896102 |
| Start date: | 01-05-2020 |
| End date: | 17-12-2022 |
| Total budget - Public funding: | 219 312,00 Euro - 219 312,00 Euro |
Cordis data
Original description
Breast cancer is the most common cancer in women worldwide. Familial breast cancer (FBC) is expected to account for up to 15% of breast cancers. Although recent breakthroughs have resulted in the identification of distinct new groups of genetically inherent breast cancer genes, about 64% of the genetic predisposition to FBC remains unexplained. Therefore, new approaches are required to identify remaining genetic factors underlying FBC susceptibility. This is crucial because the elucidation of inherent cancer defects offers the ability to counsel and monitor patients. Importantly, it also provides firm ground for therapeutically targeting particular cancer pathways for example through Poly ADP-ribose polymerase inhibitors (PARPi) that exploit synthetic lethality with particular DNA repair deficiencies.To advance the field, my host lab has performed High-Throughput phenotypic screen, based on gene variants recognized in a FBC cohort of 135 early-onset (age
Status
CLOSEDCall topic
MSCA-IF-2019Update Date
28-04-2024
Images
No images available.
Geographical location(s)
